Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merck and other ETFs, options, and stocks.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
72,000
Employees72,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
72,000
Employees72,000

MRK Key Statistics

Market cap
332.26B
Market cap332.26B
Price-Earnings ratio
146.05
Price-Earnings ratio146.05
Dividend yield
2.29%
Dividend yield2.29%
Average volume
7.55M
Average volume7.55M
High today
$131.91
High today$131.91
Low today
$130.13
Low today$130.13
Open price
$130.13
Open price$130.13
Volume
7.76M
Volume7.76M
52 Week high
$133.10
52 Week high$133.10
52 Week low
$99.14
52 Week low$99.14

MRK News

Simply Wall St 18h
Merck & Co., Inc. Just Released Its First-Quarter Earnings: Here's What Analysts Think

Merck & Co., Inc. (NYSE:MRK) just released its quarterly report and things are looking bullish. The company beat expectations with revenues of US$16b arriving 3...

Merck & Co., Inc. Just Released Its First-Quarter Earnings: Here's What Analysts Think
Benzinga 2d
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook

Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter...

Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Benzinga 3d
S&P 500 Down Over 1%; Merck Increases 2024 Outlook

Loading... Loading... U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling by around 250 points on Thursday. The Dow traded down...

S&P 500 Down Over 1%; Merck Increases 2024 Outlook

Analyst ratings

83%

of 29 ratings
Buy
82.8%
Hold
13.8%
Sell
3.4%

More MRK News

Yahoo Finance 3d
Merck raises 2024 guidance on cancer drug demand

Shares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading the p...

Merck raises 2024 guidance on cancer drug demand
Quartz 3d
Merck's stock rises on sales of its blockbuster cancer drug Keytruda

HGTV's Property Brothers react to mortgage rates rising over 7% CC Share Subtitles Off English view video HGTV's Property Brothers react to mortgage rates risi...

Merck's stock rises on sales of its blockbuster cancer drug Keytruda
Simply Wall St 3d
We Think Merck Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how ris...

We Think Merck Can Stay On Top Of Its Debt
Yahoo Finance 3d
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie - Yahoo Finance

For Immediate Release Chicago, IL – April 25, 2024 – Today, Zacks Equity Research discusses Eli Lilly LLY, Novo Nordisk NVO, Merck MRK and AbbVie ABBV. Indust...

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie - Yahoo Finance
Yahoo Finance 3d
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda - Yahoo Finance

By Patrick Wingrove (Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer dru...

Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda - Yahoo Finance
Seeking Alpha 3d
Bristol-Myers stock falls despite Q1 beat - Seeking Alpha

Shares of Bristol-Myers Squibb dipped in the premarket Thursday even as the company’s Q1 2024 results exceeded expectations amid headwinds to key components in...

Bristol-Myers stock falls despite Q1 beat - Seeking Alpha
TipRanks 3d
MRK Earnings: Merck Delivers Q1 Earnings Beat

Merck (NYSE:MRK) delivered a Q1 earnings beat on Thursday, with reporting adjusted earnings reaching $2.07 per share, compared to $1.40 per share in the same pe...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.